GLP1R and Parkinson disease: A systematic review and meta-analysis illustrated that treatment with GLP-1 agonists in preclinical rodent models of PD showed a substantial reduction in motor symptoms and dopaminergic neurotransmission, suggesting neuroprotective benefits in these models [73].